Equities analysts expect Proteon Therapeutics Inc (NASDAQ:PRTO) to post earnings per share (EPS) of ($0.33) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Proteon Therapeutics’ earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.31). Proteon Therapeutics also posted earnings of ($0.33) per share in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Monday, August 6th.
On average, analysts expect that Proteon Therapeutics will report full-year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.92) to ($1.27). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.27) per share, with EPS estimates ranging from ($1.51) to ($0.78). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Proteon Therapeutics.
Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC boosted its position in Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 201,500 shares of the biopharmaceutical company’s stock after purchasing an additional 29,600 shares during the period. Renaissance Technologies LLC owned about 1.14% of Proteon Therapeutics worth $383,000 as of its most recent filing with the SEC. 50.60% of the stock is currently owned by institutional investors.
Shares of NASDAQ PRTO opened at $2.70 on Monday. The stock has a market capitalization of $47.72 million, a PE ratio of -1.27 and a beta of 1.52. Proteon Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $2.90.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.